Sumitomo Mitsui Trust Group
ABCL icon

Sumitomo Mitsui Trust Group’s AbCellera Biologics ABCL Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62,759
Closed -$186K – 1054
2024
Q2 		$186K Hold
62,759
– – ﹤0.01% 1053
2024
Q1 		$284K Hold
62,759
– – ﹤0.01% 1081
2023
Q4 		$358K Hold
62,759
– – ﹤0.01% 1069
2023
Q3 		$289K Buy
62,759
+15,870
+34% +$96.5K ﹤0.01% 1091
2023
Q2 		$303K Hold
46,889
– – ﹤0.01% 1094
2023
Q1 		$354K Hold
46,889
– – ﹤0.01% 1095
2022
Q4 		$475K Buy
46,889
+4,053
+9% +$46.8K ﹤0.01% 1109
2022
Q3 		$424K Buy
+42,836
New +$470K ﹤0.01% 1136

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return